Skip to content
Review

Abstract C015: Clinicogenomic characterization of diffuse hemispheric glioma presenting pre-operatively with tumor-associated bleeding

Sep 2026 · Cancer Research · Vol 86, pp. C015-C015 · 0 citations

TL;DR

Clinogenomic characterization of diffuse hemispheric glioma presenting pre-operatively with tumor-associated bleeding suggests survival, transcriptional, and mutational differences for pediatric DHG patients presenting with tumor-associated bleeding are suggested.

Abstract

Pediatric diffuse hemispheric glioma (DHG) is a histone-mutated (H3.3G34R/V) high-grade glioma with poor prognosis. Clinical observation and prior reports identify that some patients with H3-mutated DHG can present with tumor-associated bleeding. Here, we sought to identify clinical and molecular characteristics predictive of bleeding risk in this tumor population. Clinical data was obtained through chart review after de-identification by the Children’s Brain Tumor Network in accordance with the institutional review board. Presence of blood products was determined on preoperative magnetic resonance imaging (MRI) by a board certified pediatric neuroradiologist. Molecular data was abstracted through The Open Pediatric Cancer Project (OpenPedCan). Transcriptomic and genomic analyses were completed in R 4.3.1 using edgeR, msigdbr, and xCell. 15 patients with H3-mutant DHG were identified at our institution. Six presented with acute intraparenchymal hemorrhage, while five had evidence of intratumoral blood products on pre-operative MRI. Four patients showed no pre-operative evidence of tumor-associated bleeding. No significant differences in clinical characteristics were observed between patients presenting with or without bleeding; however, patients presenting with bleeding demonstrated a trend toward shorter overall and progression-free survival. Bulk transcriptomic data was available for ten (67%) of these patients, six from the bleeding cohort and all four without. Increased expression of VEGFA (log fold change [LFC]: 3.45, p = 2E-07) and CA9 (LFC: 5.97, p = 8E-05) was seen in patients with tumor-associated bleeding. From a cohort of 34 H3-mutant DHGs from OpenPedCan, 11 samples with high expression (AngioHi) and 11 samples with low expression (AngioLo) of both VEGFA and CA9 (AngioHi) were compared. AngioHi samples demonstrated preferentially higher IL8 expression (LFC: 3.56, p = 0.01) with expression patterns suggestive of increased tumor-associated macrophage populations. Alterations to PTEN, FBXW7, and PDGFRA were more frequently observed in the AngioHi cohort. We suggest survival, transcriptional, and mutational differences for pediatric DHG patients presenting with tumor-associated bleeding. These data can inform future, larger-scale studies, which will be necessary to confirm the validity of these findings and investigate the potential for targeted therapeutics. Additional work is ongoing to determine if these patterns are generalizable across other pediatric high-grade glioma subtypes presenting with tumor-associated bleeding. Nikhil Joshi, Patrick J. Beck, Rakesh Murugesan, Sina Bagheri, Ezra Beaubien, Natalie Mamaril, Sreehita Hajeebu, Ali Nabavizadeh, Cassie Kline, Peter Madsen, Jessica B. Foster. Clinicogenomic characterization of diffuse hemispheric glioma presenting pre-operatively with tumor-associated bleeding [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Bridging Discovery and Clinical Impact in Pediatric Cancer; 2026 Sep 22-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_1):Abstract nr C015.

View source

Similar papers

Open access Nov 2026

Case Report: Multimodal treatment of pediatric H3G34-mutant diffuse hemispheric glioma: a safety and feasibility case report combining precision medicine and tumor treating fields with conventional care

A case of a 13-year-old boy with H3G34-DHG who underwent a multimodal treatment strategy, combining backbone chemotherapy, radiotherapy, surgery, tumour treating fields with Wilms Tumour-1 (WT1) directed dendritic cell immunotherapy and targeted therapy (STAT3-inhibition) supports the feasibility of combining multiple...

Toon van Genechten, A. Claviez, S. Oberbeck et al. · 0 citations
Review Open access Sep 2026

Gliomas with pleomorphic and pseudopapillary features (GPAP) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

Abstract DNA methylation profiling of CNS tumors led to the identification of HPAP (high‐grade glioma with pleomorphic and pseudopapillary features), a recently proposed entity with variable morphology, recurrent MAP‐kinase pathway activating events, and longer survival compared to glioblastoma. We aimed to independent...

A. Picca, Valeria Barresi, A. Trinquet et al. · 0 citations
Sep 2026

Abstract PR009: Using omics technologies to understand hepatoblastoma heterogeneity and identify tumor cell types and their microenvironment for precision medicine

Hepatoblastoma (HB) is the most common primary pediatric liver cancer. Among childhood tumors, it has one of the highest mortality rates with 20% cases resulting in death or liver transplantation. Identifying high-risk tumors has been challenged by tumor heterogeneity. Current clinical high-risk stratification re...

Elise Lelou, Abhishek Murti, Saphia Nguyen et al. · 0 citations
Case report Open access Oct 2026

Adult Thalamic Diffuse Midline Glioma, H3 K27-Altered, With KRAS Comutation and Potential Early Subependymal Dissemination

The case of a 54-year-old adult patient with a left thalamic DMG, H3 K27-altered, World Health Organization (WHO) grade 4, harboring pathogenic H3F3A K27M, KRAS G12V, and PHF6 mutations is presented and the potential biological implications of a KRAS comutation in this rare entity are discussed.

Muralidhar Idamakanti, R. Bijjam, Yasvin Onkarappa Mangala · 0 citations
Open access Nov 2026

Clinicopathologic and Molecular Features of H3 K27M-Mutant Diffuse Midline Glioma Across the Age Spectrum

Background and Objectives: Diffuse midline glioma (DMG), H3 K27-altered, occurs in children and adults, but age-group differences and their prognostic significance remain uncertain. We examined clinicopathologic and molecular features and survival in H3 K27M-mutant DMG across age groups. Materials and Methods: This ret...

B. Lee, H. Kim, H. Lee et al. · 0 citations
Open access Oct 2026

Molecular Reclassification of Diffuse Gliomas: A Feasibility Study of Clinical Features and Survival Outcomes in Colombia

The feasibility of applying the 2021 World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) to adult diffuse gliomas in Colombia was evaluated, and female sex was associated with longer survival in unadjusted analysis.

Edgar G. Ordóñez-Rubiano, F. Rodríguez, Cristian F. Siabato-Vargas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.